Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 5Glioma 4Multiple Myeloma 3Carcinoma, Non-Small-Cell Lung 3Neurofibromatosis 1 2Neoplasms 2Lymphoma 2Lung Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Colorectal Neoplasms 2Astrocytoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Juvenile 1Histiocytosis, Langerhans-Cell 1Ganglioneuroma 1

Interventions

pembrolizumab 19Specimen Handling 19Biopsy 13Magnetic Resonance Spectroscopy 12Carboplatin 11Paclitaxel 10Pemetrexed 8Nivolumab 7Irinotecan 7Gemcitabine 7trastuzumab deruxtecan 6Fulvestrant 6Radiosurgery 5Leucovorin 5Fluorouracil 5Cisplatin 5Cetuximab 5Bevacizumab 5palbociclib 4durvalumab 4Taxes 4Oxaliplatin 4Letrozole 4Docetaxel 4ribociclib 3olaparib 3Trastuzumab 3Panitumumab 3Midazolam 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × trametinib × 30 days × Clear all
NCT02079740 2026-05-28

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡